Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
Posts by this author
To address the budgeting challenges experienced by global sponsors and CROs during study start-up, Greenphire’s Catherine Click, Director, Clinical Pricing & Analysis, and Kyle Cunningham, Chief Product Officer will be discussing the four key budgeting challenges faced by sponsors and CROs which can hinder global study success in an upcoming webinar on Thursday June 18, 2020 at 2:00pm ET.
Today, Greenphire, the global leader in financial lifecycle management for clinical trials, announced the launch of a new budget development solution, EnvisiX, to address the budgeting challenges experienced by global sponsors and CROs during study start-up.
Integrated with eClinicalGPS, Greenphire’s industry-leading site payment solution, enables unprecedented simplicity and efficiency throughout a trial from budget creation and negotiation to management, execution, and tracking of global investigator grants.
As the COVID-19 pandemic continues to limit movement all over the world, clinical trials have had to adapt by leveraging methodologies typically associated with hybrid or remote clinical trial designs. The alternative would be to suspend the trial and interrupt care for enrolled patients, something that according to NPR, has been done to more than 400 studies since March 1, 2020.
To help keep trials active and patients engaged during trial disruption, Greenphire, the global leader in financial software for clinical trials, today announced that it has enhanced its award-winning payment and reimbursement solution, ClinCard, to include additional capabilities to support decentralized clinical trials due to COVID-19 interruptions.
“As the landscape for clinical trials evolves, we’re beginning to see a need for remote payment capabilities. We heard from over 1,800 site personnel and over 80% said that providing a small payment following a virtual visit would improve the likelihood of participants staying in a clinical trial,” said Kyle Cunningham, Chief Product Officer of Greenphire. “It’s of utmost importance to keep clinical trials running in this uncertain time. As a company dedicated to removing barriers to both sites and patients, we’re thrilled to offer these new capabilities for our ClinCard solution so that patients can stay engaged and enrolled in trials and sites can continue their critical work.”